Epi Biotech Co., Ltd.
Founded 2015, KONEX-listed Epi Biotech develops a hair-loss pipeline spanning dermal papilla cell, antibody, and gene therapies.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2015 and listed on KONEX in 2023, Epi Biotech develops hair loss treatments. EPI-001, an autologous dermal papilla cell therapy, received IND approval and entered Phase 1/2a trials; the pipeline also includes EPI-002, EPI-005, EPI-007, and EPI-008. EPI-005 has completed antibody production against target CXCL12, while over 200,000 people in Korea are treated for hair loss yearly.
Clinical trials
data.go.kr1 MFDS clinical trial authorisations · 2023 (Phase 1/2a 1)
- Phase 1/2aEPI-0012023-12-20
1 trial site
R&D and key agreements
Source: DART corporate disclosureEPI-001 · 안드로겐 탈모증(남성형, 여성형) · 임상 1/2a상 · Autologous dermal papilla cell hair-loss therapy; received IND approval from Korea's MFDS and entered Phase 1, with proprietary dermal papilla cell isolation/culture technology and related patents.
EPI-002 · 안드로겐 탈모증(여성형) · 비임상/CMC 개발 · Topical hair-loss treatment; completed in vitro/in vivo efficacy testing and is developing CMC processes while preparing nonclinical toxicity and efficacy studies.
EPI-005 · 원형탈모 및 안드로겐 탈모증 · 전임상(항체 개발) · Alopecia areata antibody therapy; secured the CXCL12 target affecting the hair growth cycle and completed antibody production, with binding-affinity optimization underway and CMC development planned for Q4.
EPI-007 · 원형탈모 · 전임상 · Hair-loss gene therapy; efficacy demonstrated in animal studies and mechanism-of-action research completed, with nonclinical safety studies planned.
EPI-008 · 안드로겐 탈모증(남성형, 여성형) · 전임상(원료세포 개발) · Allogeneic dermal papilla cell hair-loss therapy; researching a hypoxic culture method to reduce expression of immunogenic proteins, and preparing candidate source cells for productization.
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition